KUALA LUMPUR: Duopharma Biotech Bhd, which recorded stronger earnings in the third quarter ended Sept 30, will push ahead with its foray into specialty products as one of its strategies to create a pool of niche products.
The company in a statement yesterday said that it had recently obtained registration approval and launched Erysaa, an Erythropoeitin (EPO) product. EPO is the protein present in the human body that adjusts the red blood cell generation in accordance with the oxygen requirement of the human body.
Recombinant version of EPO is used as the therapeutic agent of all anemia patients, acute anemia in kidney dialysis patients, anemia due to anti-cancer chemotherapy and patients requiring blood transfusion.
However, Duopharma pointed out the recent strengthening of US dollar globally poses challenges as it affects its production and other operational costs.
“It is expected to put pressure on manufacturing margin and hence our profit ."
In the third quarter ended Sept 30,2019, its net profit increased by 20.9% to RM14.86mil from RM12.28mil a year ago, while revenue increased by 13.5% to RM142.85mil from RM125.84mil.
Did you find this article insightful?